重组人催乳素对大鼠子宫内膜异位模型作用的研究

Study on the effect of recombinant human prolactin on rat endometriosis model

目的: 利用动物模型, 外源性给予重组人催乳素(rhPRL), 探讨PRL在子宫内膜异位症(EM) 发生、发展中的作用。方法: 先建立大鼠子宫内膜异位症(EM) 模型50只, 将建模成功大鼠随机分为6组: 实验1组10例, 实验2组10例, 实验3组10例, Danazol对照组10例, 生理盐水对照组6例, 空白对照组4例。然后用不同浓度的rhPRL〔50μg/ (kg·d)、100μg/ (kg·d)、200μg/ (kg·d)〕给实验大鼠腹腔内注射, Danazol对照组灌喂Danazol〔(80mg/ (kg·d)〕; 生理盐水对照组以与实验组等量的生理盐水腹腔内注射; 空白对照组不加干预。观察指标: 肉眼观察EM模型的消长及粘连情况, 用流式细胞术测定CD3、CD4、CD8T淋巴细胞, 用ELISA法测量血清中IL-2、IL-4的含量。结果: 用中、低浓度rhPRL治疗后CD4 /CD8比值升高, 与生理盐水及空白对照组相比有显著性差异(P<0 .05)。用中、低浓度rhPRL治疗后, 大鼠体内白细胞介素IL-4水平下降, 而IL-2却明显升高, 与生理盐水及空白对照组相比均有显著性差异(P<0 .05)。用rhPRL治疗后, 异位病灶缩小, 粘连受到明显的抑制, 与Danazol对照组相比无明显差异(P>0. 05), 与生理盐水及空白对照组有显著性差异(P<0 .05)。结论: 恰当计量的重组人催乳素可以通过参与机体的免疫调节,

Objective:To explore the effect of recombinant human prolactin (rhPRL) on endometriosis (EM).Methods:50 rat models with EM were established firstly and were randomly divided into study group 1 (10 cases, with 50μg·kg -1 ·d -1 of rhPRL ), group 2 (10 cases, with 100 μg·kg -1 ·d -1 of rhPRL), group 3 (10 cases, with 200μg·kg -1 ·d -1 of rhPRL), Danazol control group (10 cases, with 80 mg·kg -1 ·d -1 of Danazol), saline control group (6 cases) and blank control group (4 cases).Diameter and conglutination of nidus were measured and observed, CD3, CD4 CD8 T lymphocyte was determined by flowcytometry, serum IL-2 and IL-4 were determined by ELISA.Results:CD4/CD8 in group 1 and group 2 were significantly higher than those in saline group and blank controls ( P <0.05).IL-4 levels decreased but IL-2 significantly increased in group 1 and 2 comparing to that in saline group and blank controls ( P <0.05).EM niduser shrinked and conglutination was inhibited in study groups comparing to Danazol controls ( P >0.05) and saline group and blank controls ( P <0.05).Conclusion:The right dosage of rhPRL could play inhibition or treatment role in growth and conglutination of rat EM model by participating in immune regulation.